Swiss Re Turns To Profit In Q1, Premiums Rise; Sees Strong Underlying Performance Ahead

News, market analysis, investment scam prevention tips and more ✔️ Your source for latest asset management news and information. This magazine is crafted specifically for those who are interested in diving into the global asset management world. (RTTNews) - Swiss Re Group (SSREY.PK) reported Friday that its first-quarter Group net income was $333 million, compared to last year's loss of $225 million. The strong underlying performance of all businesses more than offset losses related to COVID- 19 and large natural catastrophes. Excluding COVID-19-related claims and reserves, Swiss Re's net income was $843 million, up from $158 million a year ago. Property and Casualty Reinsurance or P&C Re net income was $477 million, significantly higher than last year's $61 million. Excluding COVID-19 impacts, P&C Re's net income was $509 million. Life and Health Reinsurance net loss was $184 million. Excluding COVID-19 losses, net income was $270 million. Consolidated net premiums earned and fee income increased to $10.21 billion from last year's $9.59 billion. P&C Re's net premiums earned increased 5.7 percent to $5.0 billion. Life and Health Reinsurance net premiums earned and fee income increased 13.8 percent to $3.8 billion. Looking ahead, Swiss Re's Group Chief Executive Officer Christian Mumenthaler said, "We have seen a solid start to 2021 and expect all our businesses to continue delivering a strong underlying performance with diminishing COVID-19 losses." To keep reading about Swiss Re Turns To Profit In Q1, Premiums Rise; Sees Strong Underlying Performance Ahead, Click on the link. Seoul, Korea
http://dlvr.it/Ryl84R

Comments

Post a Comment

Popular posts from this blog

AstraZeneca Begins Phase I Trial Of AZD7442 Against COVID-19 – Quick Facts

Image
(RTTNews) - AstraZeneca Plc (AZN.L, AZN) said first participants have been dosed in a Phase I trial of AZD7442 for the prevention and treatment of COVID-19. The trial will evaluate the safety, tolerability and pharmacokinetics of AZD7442. It will include up to 48 healthy participants in the UK aged 18 to 55 years. AZD7442 is a combination of two monoclonal antibodies derived from convalescent patients with SARS-CoV-2 infection. Discovered by Vanderbilt University Medical Center and licensed to AstraZeneca in June 2020, the mAbs were optimised by AstraZeneca. Data readout from the trial is anticipated in the second half of 2020. To keep reading about AstraZeneca Begins Phase I Trial Of AZD7442 Against COVID-19 – Quick Facts, Click on the link. Seoul, Korea http://dlvr.it/RfHgSK
Read more

Coronavirus Hasn't Diminished Tech Stocks' Allure

Image
FYI: By Caitlin McCabe Caitlin McCabe The Wall Street Journal Biography caitlin.mccabe@wsj.com Updated April 20, 2020 6:14 pm ET The FANG trade hasn’t lost its bite. Big technology stocks are again charging to new heights and propelling the broader stock market, which is swiftly rebounding after a punishing selloff. The NYSE FANG+ index—which comprises Facebook Inc., FB -0.56% Amazon.com Inc., AMZN 0.78% Netflix Inc. NFLX 3.44% and Google parent Alphabet Inc., GOOG -1.30% along with Apple Inc., AAPL -2.08% Twitter Inc., Tesla Inc., TSLA -1.00% Nvidia Corp. NVDA -1.80% and the Chinese behemoths Alibaba Group Holding Ltd. and Baidu Inc. —is up 11% year-to-date after a dramatic rally last week. The four FANG stocks added $251 billion in market value last week, their biggest gain on record dating to Facebook’s 2012 initial public offering. The S&P 500, in comparison, is down 13% in 2020 but has r
Read more

Henlius Plans to File the NDA of Novel anti-PD-1 mAb HLX10 for the Treatment of MSI-H Solid Tumours, the Phase 2 Clinical Trial has Met the Primary Endpoint

News, market analysis, investment scam prevention tips and more ✔️ Your source for latest asset management news and information. This magazine is crafted specifically for those who are interested in diving into the global asset management world. SHANGHAI, March 28, 2021 /PRNewswire/ -- Shanghai Henlius Biotech, Inc. (2696.HK) announced that the Phase 2 study of its innovative PD-1 inhibitor HLX10 in patients with unresectable or metastatic microsatellite instability-high or mismatch repair-deficient (MSI-H/dMMR) solid tumors that fail to respond to the standard therapy has met the primary endpoint. Henlius plans to file a New Drug Application (NDA) to the National Drug Products Administration (NMPA) for the treatment of MSI-H solid tumours based on the results from the Phase 2 trial of HLX10, which will be presented at upcoming medical conferences. Professor Shukui Qin of No.81 Hospital of People's Liberation Army and Professor Jin Li of Shanghai East Hospital affiliated to Shang
Read more